Immunotherapy

Personalized Anticancer Vaccine

The presented fully personalized immunotherapeutic anti-tumor vaccine is using the immunization property of sporadic cells (circulating tumor cells) and their parts.

The continuous testing of circulating tumor cells presence/absence defines the timing of vaccine production and its administration to the patient. The patient monitoring relies on the real – time sporadic cell assessment (MetaCellTM).

The 100% autologous vaccine can be used to induce a personalized anti-tumor immune response in autologous vaccination, which causes an immunogenic reaction in the organism against the currently present tumor cells.

The vaccination process is monitored by repeated monitoring of circulating tumor cells appearance.